Thank you for submitting your manuscript for consideration by The EMBO Journal. It has now been seen by three referees whose comments to the authors are shown below. As you will see, the reviewers are somewhat divided in their recommendations. Referee 1 is not in favour of publication of the paper here -mainly as he/she is not convinced that you make a sufficiently strong case for the physiological significance of your findings, in particular in the light of Hasselblatt et al. Oncogene 27, 6102, 2008 . Referee 3 also expresses certain hesitations, but at the same time comes up with a number of constructive suggestions that could help to strengthen the in vivo part of the study. Referee 2 is the only one of the referees who is clearly positive and strongly supports publication of the study here. I have now had a chance to look into the manuscript, the reports and the paper by Hasselblatt et al. in depth. Furthermore, I have consulted with our Executive Editor who also looked into the matter in depth. We have come to the conclusion that we should be able to give you the chance to strengthen the study along the line suggested by the referees and in particular to strengthen the in vivo part of the study including the mouse tumorigenesis experiment using APC mutant background and c-Jun mutant mice as well as evidence from human colorectal carcinomas along the lines suggested by referees 1 and 3. We also have two minor points: Please the check bar annotation in figure 4H . Please quantify the ChIP data, including replicates to generate error bars (figure 4H, figure S3 ). We also agree with referee 3 that figure 6 may not really be helpful.
I should remind you that it is EMBO Journal policy to allow a single round of revision only and that, therefore, acceptance or rejection of the manuscript will depend on the completeness of your responses included in the next, final version of the manuscript as well as on the addition of stronger and more definitive data on the physiological significance of your findings.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Referee #1 (Remarks to the Author):
In this manuscript, Behrens and colleagues address the role of JNK/Jun signaling in the homeostasis of the intestinal epithelium. They show that c-Jun regulates the levels of TCF4, the most downstream component of the Wnt pathway, by direct binding to its promoter. Manipulation of Jun/JunK activity in vivo modifies the levels of the Wnt-driven crypt progenitor gene programme. They put forward the notion that JNK signaling regulates the function of progenitor crypt cells through the cross-talk with the Wnt pathway. Obviously this is an interesting and novel idea which is unfortunately not supported by their data. Transgenic mice with exacerbated JNK signaling in the intestine or lacking c-Jun show no gross abnormalities in the morphology or physiology of the epithelium. The defects reported in cell proliferation and villus length in these mice models are rather mild. From the data presented, this reviewer can only conclude that the described crosstalk between the Wnt and JNK signaling pathways only plays a minor role in the regulation of the biology of the intestinal epithelium in normal conditions. Indeed, a recent report by Erwin Wagner group (Hasselblatt et al. Oncogene 2008) could not detect any phenotype in the intestine of c-jun conditional knock-out mice neither defects in intestinal tumor formation or bowel inflammation.
The manuscript contains several other issues that also require clarification: 4.It has been reported that the expression of TCF4 is higher in the villus compared with the crypts. Furthermore, Hasselblatt et al. (Oncogene 2008 ) also showed that c-jun expression is restricted to differentiated cells in the small intestine. Therefore, the upregulation of Tcf4 shown by western-blot is likely occurring in the villus rather than at the crypt base.
5.To conclusively validate the role of JNK in tumorigenesis, AOM/DSS experiments should be also performed in a c-jun negative background (i.e. using c-Jun∆G mice or JunAA mice, which have been used as a model by the authors in previous works).
6.As a general recommendation, the authors should provide low magnification pictures showing arrays of crypt and villus rather than single units. This will provide a broader picture and would strength the relevance of the data.
Referee #2 (Remarks to the Author):
The manuscript by Sancho et al extends previous work by the Behrens group on the role on C-Jun in intestinal homeostasis and tumourigenesis. This work has been somewhat contentious given that Wagner group find that C-Jun loss does not affect AOM/DSS tumourigenesis or the phenotypes following Apc loss. Thus it is very important to ascertain the significance of Jun and JNK signalling to intestinal homeostasis and tumourigenesis.
In this manuscript Sancho et al provide robust evidence that JNK overexpression is sufficient to increase proliferation of the intestinal crypt resulting in increased villus length. Importantly the mechanism of this is shown via genetic knockout of Jun. Novel insights are provided in the interaction between Wnt and JNK signalling. They then provide strong evidence that increased JNK signalling drives tumourigenesis. Overall I think this is a very nice manuscript meriting publication.
Minor points. 1. I'm not impressed by the caspase 3 IHC. Generally it is thought the apoptosis within the intestinal epithelium occurs in the intestinal crypt or as cells are sloughed off the villus. The stained cells here are not being sloughed off or in the intestinal crypt. Indeed they look to me like sticky goblet cells. If the authors want to include this data they should use a second measure of apoptosis either histological counts off H&E sections or TUNEL assays. 2. It was unclear to me if the authors were arguing for more CBCs in the JNK overexpressing crypts and less in the JUN knockouts. Did LGR5 ISH change in the Jun knockouts. 3. They cited that Cyclin d1 is an intestinal wnt target gene, there is some dispute over this and the authors should add that caveat to the paper. To me it looks more like a joint WNT/JUN target gene 4. Given the tumourigenesis was done in the colon following AOM/DSS treatment, some comment on the phenotype of JNK overexpression in colonic crypts should be made eg do they have hyperproliferation etc 5. Although they mention they fact the JNK1 KO mice are tumour prone, they should mention the Wagner/Hassleblatt paper on JUN KO as well and the lack of affect of JUN and other family members on the AOM/DSS model of colon carcinogenesis Referee #3 (Remarks to the Author):
The paper by Sancho et al reports gain and loss of function analyses of JNK signaling in the mouse gut.
These are interesting studies that advance our understanding of JNK signaling in the intestine and its stem cells. However, it falls somewhat short in the development of a clear mechanism for JNK or cjun action in this context.
The gain-of-function studies rely on a JNKK2-JNK1 construct that may or may not recapitulate normal signaling. It is an interesting tool but the authors need to clearly validate it in normal colon or colorectal cancer cells.
The in vivo studies show some very minor effects in BrdU incorporation ( Fig. 1F ) and villus length ( Fig. 1D ), although the phenotype is indeed interesting. One wonders, however, about the strength of signaling driven by their artificial construct.
The authors need to show and quantify the state and number of differentiated cells (e.g. goblet cells) per villus in the floxed vs defloxed lines.
One recurrent and key problem here and elsewhere is the lack of clarification of the cell autonomy of the effects reported. It is unclear if increased marker expression means increased expression per cell due to more signaling in a cell autonomous manner or an increase in expressing cells. This is a key distinction that needs to be addressed and resolved before acceptance.
The authors should comment why different parts of the gut respond differently to increased signaling and loss of cjun as shown in Figs. 1D, 3C.
The tumorigenic model provides a convincing result in terms of the number of tumor per mice. However, it does not directly address a possible cross-talk with bcatenin. The paper would be much improved by the addition of analyses of the gain and loss of function lines used in this study in an APCfl/fl or Apc min background.
The number of bcat+ cells shown in Fig. 5G ,H should be quantified. Do cells that have high levels of cJun harbor nuclear bcat (Fig. 5G,I ,H,J)?
The tumorigenic results should be more cautiously presented. Do these tumors develop into carcinomas? Can the authors provide clear evidence in human colorectal carcinomas that JNK or cjun activities are critical for growth or tumor progression?
The last figure is not helpful. I am unable to understand exactly what the authors mean. This may reflect the difficulty to derive a clear mechanism of action from the presented data.
Finally, the title should reflect the nature of the experiments more directly. A suggestion would be to mention that the experiments were done in mice and to delete or soften the 'tumorigenic' part. As you will see, we have performed all the requested experiments and have addressed in depth all essential points of criticism. Importantly, we provide new data in the revised manuscript that suggest a molecular explanation for the apparent discrepancies in published data on JNK/c-Jun signalling in intestinal cancer. Thus, we believe to have significantly strengthened our manuscript and I hope the reviewers will share this view.
In this manuscript, Behrens and colleagues address the role of JNK/Jun signaling in the homeostasis of the intestinal epithelium. They show that c-Jun regulates the levels of TCF4, the most downstream component of the Wnt pathway, by direct binding to its promoter. Manipulation of Jun/JunK activity in vivo modifies the levels of the Wnt-driven crypt progenitor gene programme. They put forward the notion that JNK signaling regulates the function of progenitor crypt cells through the cross-talk with the Wnt pathway. Obviously this is an interesting and novel idea which is unfortunately not supported by their data. Transgenic mice with exacerbated JNK signaling in the intestine or lacking c-Jun show no gross abnormalities in the morphology or physiology of the epithelium.
The defects reported in cell proliferation and villus length in these mice models are rather mild.
Proliferation in JNKK2-JNK1 transgenic mice is increased by 30% in transit amplifying cells and by 40% in CBC cells. In contrast to this reviewer, we actually felt that this was a surprisingly large difference. Statistical analysis reveals that this difference is highly significant (P<0,01).
From the data presented, this reviewer can only conclude that the described crosstalk between the Wnt and JNK signaling pathways only plays a minor role in the regulation of the biology of the intestinal epithelium in normal conditions. Indeed, a recent report by Erwin Wagner group (Hasselblatt et al. Oncogene 2008) could not detect any phenotype in the intestine of c-jun conditional knock-out mice neither defects in intestinal tumor formation or bowel inflammation.
We will address the conflict between our paper and the Hasselblatt et al. paper below.
The manuscript contains several other issues that also require clarification:
1. Detection of activated c-jun is used as an indirect measure of the expression of the JNKK2-JNK1 transgene in crypt base columnar cells (aka intestinal stem cells 2. Authors must explore if the activation of JNK pathway results in a expansion of the ISC numbers. Also, data on ISC proliferation and marker gene expression in mice deficient for c-jun is lacking.
We have performed the suggested experiments. We have added: a) quantification of CBC cell number in JNNK2-JNK1∆G and c-jun∆G mice (new Figures 2F, 3G) and b) lgr5 marker gene expression in c-jun∆G mice (new Figures 3F, 3H). There is a trend that ISC number is higher in JNNK2-JNK1∆G and lower is c-jun∆G mice, but the differences are small and not significant. Thus JNK/c-Jun modulate CBC cell proliferation but not number.
3. The effect over apoptosis is unclear. The arrowheads in sup fig 1 seem to point towards enteroendocrine cells, which usually give high background on IHC. Authors should provide an alternative assessment of apoptosis (i.e. TUNEL). Figure 4) .
We have performed a TUNEL staining as an independent marker for cell death and found no difference between JNNK2-JNK1∆G and control mice (new Supplementary

It has been reported that the expression of TCF4 is higher in the villus compared with the crypts. Furthermore, Hasselblatt et al. (Oncogene 2008
) also showed that c-jun expression is restricted to differentiated cells in the small intestine. Therefore, the upregulation of Tcf4 shown by western-blot is likely occurring in the villus rather than at the crypt base. (Figures 2A, B; 3A; Supplementary Figure 5 ). Our data were nicely confirmed by a recent paper by the Clevers lab (van der Flier LG; Cell. 2009 136(5):903-12) 
Whereas Hasselblatt et al. indeed show that c-Jun is expressed in the villus, we show that c-Jun is also expressed in the crypt, specifically in CBC stem cells. We have seen the same expression pattern using antibody for c-Jun and phosphorylated c-Jun
.In this study the gene signature for Lgr5-positive stem cells was determined. C-Jun was identified as one of the 95 genes that form the core transcriptome of CBC stem cells. Thus the presence of c-Jun in intestinal stem cells is beyond doubt. We feel that this reviewer does not evaluate our data impartially. He/she rejects our c-Jun expression data solely based on the fact that they are not in agreement with the Hasselblatt et al. paper. The truth is that our analysis is thorough and correct.
5. To conclusively validate the role of JNK in tumorigenesis, AOM/DSS experiments should be also performed in a c-jun negative background (i.e. using c-Jun∆G mice or JunAA mice, which have been used as a model by the authors in previous works).
This suggestion urges us to directly replicate the experiments done in the group of Erwin Wagner.
We do not see the point of doing this.
6. As a general recommendation, the authors should provide low magnification pictures showing arrays of crypt and villus rather than single units. This will provide a broader picture and would strength the relevance of the data.
We have added the suggested pictures (Supplementary Figure 2).
The manuscript by Sancho et al extends previous work by the Behrens group on the role on C-Jun in intestinal homeostasis and tumourigenesis. This work has been somewhat contentious given that Wagner group find that C-Jun loss does not affect AOM/DSS tumourigenesis or the phenotypes following Apc loss. Thus it is very important to ascertain the significance of Jun and JNK signalling to intestinal homeostasis and tumourigenesis. In this manuscript Sancho et al provide robust evidence that JNK overexpression is sufficient to increase proliferation of the intestinal crypt resulting in increased villus length. Importantly the mechanism of this is shown via genetic knockout of Jun. Novel insights are provided in the interaction between Wnt and JNK signalling. They then provide strong evidence that increased JNK signalling drives tumourigenesis. Overall I think this is a very nice manuscript meriting publication.
Minor points. 1. I'm not impressed by the caspase 3 IHC. Generally it is thought the apoptosis within the intestinal epithelium occurs in the intestinal crypt or as cells are sloughed off the villus. The stained cells here are not being sloughed off or in the intestinal crypt. Indeed they look to me like sticky goblet cells. If the authors want to include this data they should use a second measure of apoptosis either histological counts off H&E sections or TUNEL assays. Figure 4) . Figures 3F, 3H ).
We have performed a TUNEL staining as an independent marker for cell death and found no difference between JNNK2-JNK1∆G and control mice (new Supplementary
4. Given the tumourigenesis was done in the colon following AOM/DSS treatment, some comment on the phenotype of JNK overexpression in colonic crypts should be made eg do they have hyperproliferation etc We have followed this suggestion. Also in the colon JNK activation causes hyperproliferation (new Supplementary Figure 3) .
5. Although they mention they fact the JNK1 KO mice are tumour prone, they should mention the Wagner/Hassleblatt paper on JUN KO as well and the lack of affect of JUN and other family members on the AOM/DSS model of colon carcinogenesis. Figure 6A, (Fig. 1F ) and villus length (Fig. 1D) , although the phenotype is indeed interesting. One wonders, however, about the strength of signaling driven by their artificial construct.
The tumorigenic model provides a convincing result in terms of the number of tumor per mice. However, it does not directly address a possible cross-talk with bcatenin. The paper would be much improved by the addition of analyses of the gain and loss of function lines used in this study in an APCfl/fl or Apc min background. (Nateri et al, 2005) , but mice lacking c-jun show normal colitis-induced intestinal tumour formation (Hasselblatt et al, 2008) . In contrast activation of JNK signalling augments colitis-induced intestinal tumour formation but has no effect on ApcMin/+-triggered tumourigenesis. In the revised paper we provide evidence that there are molecular differences with regard to JNK activity in the 2 tumour models, and we speculate that this underlies the relative importance of JNK and c-Jun for intestinal tumour formation.
The number of bcat+ cells shown in Fig. 5G ,H should be quantified. Figure 8B ).
We have done this suggested experiments and see no significant difference between JNK1∆G and control mice (new Supplementary
Do cells that have high levels of cJun harbor nuclear bcat (Fig. 5G,I ,H,J)?
We have looked at this doing a co-IHC for beta-catenin and c-Jun (new Supplementary Figure 8A ). There is a tendency that c-Jun levels are elevated in cells with nuclear beta-catenin. Figure 6) .
Finally, the title should reflect the nature of the experiments more directly. A suggestion would be to mention that the experiments were done in mice and to delete or soften the 'tumorigenic' part.
We have changed the title to "JNK signalling modulates intestinal homeostasis and tumourigenesis in mice".
